Introduction: The first-generation Watchman 2.5 (W2.5) is associated with several limitations, including the difficulty of implantation in complex LAA anatomies, peri device leak, device recapture and device-related thrombosis. The second-generation Watchman FLX (W-FLX) addressed those limitations with proven safety and efficacy of the device.Hypothesis: This meta-analysis compares the safety and efficacy of the Watchman FLX and 2.5 devices.Methods: The meta-analysis was conducted according to PRISMA guidelines. Studies were located through a search strategy utilizing PubMed, Google scholar and MEDLINE from inception to March 20, 2022, with a primary objective to compare the safety and efficacy of the W-FLX and W2.5. After setting inclusion and exclusion criteria, we identified three recently published observational studies.Results: Our analysis included 3 studies comprising 401 patients. New generation W- FLX is associated with less incidence of major-leak compared to the first-generation W 2.5, OR: 0.08 CI (0.06-0.12) P <0.01 (Figure 1). There was no difference in mortality OR: 1.38 CI (0.00-152360) P .78, procedure success OR: 16.07 CI (0.06-4676.83) P 0.1 or post-procedural complications (Bleeding OR: 0.63 CI (0.03-13.07) P 0.31, device embolization OR: 0.12 CI (0.00-3.79) P 0.08, pericardial effusion OR: 0.14 CI (0.00-12.23) P 0.11 or stroke OR: 0.7 CI (0.00-9170) P 0.71) across the two devices.Conclusions: The new generation Watchman FLX has a superior sealing capacity than the Watchman 2.5 with a similar safety profile.